Sunovion gets FDA nod for KYNMOBI™ as Parkinson’s Disease treatment
Sunovion has announced it has received approval from the FDA for KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the treatment of
Read more
Neurology
Pfizer’s gene therapy promising for Duchenne muscular dystrophy (DMD)
Pfizer Inc. has revealed revised clinical Phase 1b results on PF-06939926, an investigational gene therapy to treat Duchenne muscular dystrophy
Read more
Roche’s OCREVUS (ocrelizumab) can half risk of MS impairment advance
New post-hoc analysis of six years of study data for Roche’s OCREVUS (ocrelizumab) shows earlier treatment initiation nearly halves the
Read more
SPRAVATO™ Nasal Spray (esketamine) Licensed in EU for treatment-resistant MDD
Esketamine is used as a fast-acting nasal spray treating patients who have not reacted well to conventional antidepressants. It is used
Read more